Age-related macular degeneration (AMD) remains a devastating cause of visual loss among elderly individuals. While considerable progress has been made towards combating the disease, most recently with intravitreal anti-VEGF agents, visual outcomes are still limited by continued retinal pigment epithelium (RPE) degeneration and subsequent neurosensory retinal atrophy. Among the promising new treatment options being explored, radiotherapy appears apt to address the multifactorial etiology of AMD. Current investigative studies underway will hopefully yield clinical efficacy to complement this theoretical suitability for arresting visual loss.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08820538.2011.554486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resveratrol Supplementation in Wet AMD: Association With Fewer Intravitreal Injections and Reduced Macular Fibrosis.
Clin Ophthalmol
January 2025
2nd Department of Ophthalmology, Medical School of University of Athens, "attikon" University Hospital, Athens, Greece.
Purpose: To evaluate the 2-year outcomes of resveratrol oral supplement given as an adjunctive treatment in patients with wet age-related macular degeneration (AMD) that were treated with intravitreal injections of aflibercept.
Patients And Methods: In our retrospective study, 50 treatment-naïve patients suffering from wet-AMD were included. They were assigned to two subgroups of 25 patients each.
Deep-Reticular Pseudodrusen-Net: A 3-Dimensional Deep Network for Detection of Reticular Pseudodrusen on OCT Scans.
Ophthalmol Sci
November 2024
National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland.
Objective: To propose Deep-RPD-Net, a 3-dimensional deep learning network with semisupervised learning (SSL) for the detection of reticular pseudodrusen (RPD) on spectral-domain OCT scans, explain its decision-making, and compare it with baseline methods.
Design: Deep learning model development.
Participants: Three hundred fifteen participants from the Age-Related Eye Disease Study 2 Ancillary OCT Study (AREDS2) and 161 participants from the Dark Adaptation in Age-related Macular Degeneration Study (DAAMD).
'Such a lot of bother': Qualitative results of a home trial of a wearable electronic vision enhancement system for people with age-related macular degeneration.
Ophthalmic Physiol Opt
January 2025
Vision and Hearing Sciences Research Centre, Anglia Ruskin University, Cambridge, UK.
Purpose: Wearable electronic low vision enhancement systems (wEVES) improve visual function but are not widely adopted by people with vision impairment. Here, qualitative research methods were used to investigate the usefulness of wEVES for people with age-related macular degeneration (AMD) after an extended home trial.
Methods: Following a 12-week non-masked randomised crossover trial, semi-structured interviews were completed with 34 participants with AMD, 64.
Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage.
Mol Ther
January 2025
Department of Molecular Medicine, University of Southern Denmark; Odense, 5230, Denmark. Electronic address:
Neovascular age-related macular degeneration and diabetic macular edema are leading causes of vision-loss evoked by retinal neovascularization and vascular leakage. The glycoprotein microfibrillar-associated protein 4 (MFAP4) is an integrin αβ ligand present in the extracellular matrix. Single-cell transcriptomics reveal MFAP4 expression in cell-types in close proximity to vascular endothelial cells including choroidal vascular mural cells and retinal astrocytes and Müller cells.
View Article and Find Full Text PDFAnalysis of quantitative OCT and SS-OCTA metrics three months after initiation of intravitreal faricimab for treatment-recalcitrant neovascular AMD.
Eye (Lond)
January 2025
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Purpose: To utilize optical coherence tomography (OCT) and SS-OCT angiography (SS-OCTA) for quantifying morphological changes seen in eyes with recalcitrant neovascular age-related macular degeneration (nAMD) transitioned to intravitreal faricimab injections during the manufacturer's recommended induction phase of treatment.
Methods: Fifty-four treatment-recalcitrant patients (60 eyes) were recruited. OCT and SS-OCTA images were obtained at 0 and 3 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!